Thermo Fisher Scientific Inc. (NYSE:TMO) has been given an average rating of “Buy” by the fifteen ratings firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $303.17.
Several research firms have commented on TMO. Bank of America restated a “buy” rating and set a $300.00 target price (up from $285.00) on shares of Thermo Fisher Scientific in a research report on Tuesday, April 16th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research report on Thursday, May 30th. They set an “outperform” rating on the stock. UBS Group upped their target price on shares of Thermo Fisher Scientific from $305.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, May 23rd. Needham & Company LLC upped their target price on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Finally, Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 target price on the stock in a research report on Wednesday, June 12th.
In related news, Director C Martin Harris sold 275 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total value of $74,450.75. Following the sale, the director now directly owns 6,433 shares of the company’s stock, valued at approximately $1,741,606.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total transaction of $14,241,500.00. Following the completion of the sale, the chief executive officer now directly owns 342,193 shares in the company, valued at $97,466,832.19. The disclosure for this sale can be found here. Insiders sold a total of 52,775 shares of company stock worth $14,986,676 over the last three months. 0.45% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. Truvestments Capital LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth about $29,000. Massey Quick Simon & CO. LLC bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $30,000. Redhawk Wealth Advisors Inc. bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $31,000. Capital Advisors Ltd. LLC boosted its stake in shares of Thermo Fisher Scientific by 250.0% during the second quarter. Capital Advisors Ltd. LLC now owns 140 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 100 shares in the last quarter. Finally, MRA Associates USA LLC bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $43,000. 88.21% of the stock is currently owned by institutional investors.
Shares of TMO traded down $3.23 during midday trading on Wednesday, hitting $271.94. 1,405,801 shares of the company traded hands, compared to its average volume of 1,600,072. The firm has a 50 day simple moving average of $287.70. Thermo Fisher Scientific has a 52 week low of $208.34 and a 52 week high of $305.45. The stock has a market cap of $110.68 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 1.81 and a beta of 1.11. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.49.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, beating the consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The business had revenue of $6.32 billion during the quarter, compared to the consensus estimate of $6.31 billion. During the same quarter in the prior year, the firm earned $2.75 EPS. The business’s revenue was up 3.9% on a year-over-year basis. On average, equities analysts anticipate that Thermo Fisher Scientific will post 12.23 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, September 17th will be given a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.83%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Further Reading: Why are trading ranges significant?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.